David M. Alvarado, PhD

---

• Epithelial biology
• Inflammatory bowel disease
• Animal models of human disease

Degrees

---

PhD: Cellular and Molecular Medicine, Johns Hopkins School of Medicine, Baltimore, MD, 2014

Bachelor of Science: Microbiology, University of South Florida, Tampa, FL, 2007

Associates: Hillsborough Community College, Brandon, FL, 2005

Postdoctoral Research, Washington University School of Medicine in St. Louis, 2020

---

Awards and Honors

---

• 2003-2004, Cynthia Mansour Mathematics Scholarship
• 2003-2004, Outstanding Service in Supplemental Instruction
• 2003-2005, Dean’s List, Hillsborough Community College
• 2004-2005, Who’s Who Among Students in American Junior Colleges
• 2004-2005, Academic Excellence in Chemistry
• 2004-2005, Outstanding Leadership in Supplemental Instruction
• 2004-2005, Outstanding Leadership in Student Government Association
• 2005-2007, NIH Minority Access to Research Careers Undergraduate Student Training in Academic Research (MARC U-STAR) Program Participant
• 2005-2007, USF Honors College Scholarship
• 2005-2007, Latino Scholars Transfer Scholarship
• 2006, Anne and Werner von Rosenstiel Undergraduate Research Symposium Award
• 2006, Outstanding Poster Presentation, USF Health Science Center Student Research Day
• 2007, Highest Achievement, MARC U-STAR Scholars Program
• 2010, Carl Storm Underrepresented Minority Fellowship, Intermediate Filaments Gordon Research Conference
• 2015, W. M. Keck Fellow, Washington University in St. Louis (declined)
• NIH T32 Training Grant appointment (3T32DK077653-24S1)
• 2016, Scientific Accomplishment as an Early Stage Investigator, Digestive Diseases Week, San Diego CA
• 2018, Poster of Distinction, Crohn’s and Colitis Congress, Las Vegas NV
• 2018, Young Investigator Travel Grant, Crohn’s and Colitis Congress, Las Vegas NV
• 2019, Scientific Accomplishment as an Early Career Investigator, Digestive Diseases Week, San Diego CA
• 2019, Lawrence C Pakula, MD IBD Research Innovation and Education Fellowship

---

• Intestinal biology during states of health
• Inflammatory bowel disorders (Crohn’s disease, ulcerative colitis, colon cancer)
• Disease-relevant cell signaling pathways

Publications

---

Alvarado, D.M.*, Son, J., Thackray, L.B., Gomez Castro, M.F., Prasad, S., Cui, X., Sonnek, N.M., Diamond, M.S., Ding, S., Ciorba, M.A.* Mesalamine Reduces Intestinal ACE2 Expression Without Modifying SARS-CoV-2 Infection or Disease Severity in Mice. Inflamm Bowel Dis. 2021 Nov 28;izab274. doi: 10.1093/ibd/izab274. *Equal contributors.

Chen B, Alvarado DM, Iticovici M, Kau NS, Park H, Parikh P, Thotala D, Ciorba MA. Interferon induced IDO1 mediates radiation resistance and is a therapeutic target in colorectal cancer. Cancer Immunol Res. 2020 Apr;8(4):451-464. doi: 10.1158/2326-6066.CIR-19-0282. Epub 2020 Mar 3. PubMed PMID: 32127391; PubMed Central PMCID: PMC7123802.

Alvarado DM, Chen B, Dai N, Iticovici M, VanDussen KL, Shaikh N, Lim CK, Guillemin GJ, Tarr PI, Ciorba MA. Epithelial IDO1 Modulates Ahr and Notch Signaling to Increase Secretory Cell Differentiation and Alter Mucus-Associated Microbiota. Gastroenterology. 2019 Jul 13. pii: S0016-5085(19)41094-9. doi: 10.1053/j.gastro.2019.07.013. Epub 2019 Jul 17. PMID: 31325428